Related Experiment Video
Updated: Jun 13, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Pemetrexed in advanced non-small-cell lung cancer
Alexander D Fuld1, Konstantin H Dragnev, James R Rigas
1Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA. Alexander.Fuld@Hitchcock.org
Pemetrexed is an effective treatment for advanced non-small-cell lung cancer (NSCLC), showing better outcomes in nonsquamous tumors. This antifolate agent also demonstrates potential in NSCLC maintenance therapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced non-small-cell lung cancer (NSCLC) treatments offer limited survival benefits, necessitating novel therapeutic agents.
- Pemetrexed has emerged as a significant treatment option for advanced NSCLC in both first- and second-line settings.
Purpose of the Study:
- To review the mechanism of action, pharmacokinetics, safety, and efficacy of pemetrexed in advanced NSCLC.
- To analyze published data on pemetrexed's clinical use in NSCLC from 1995 to 2009.
Main Methods:
- Review of peer-reviewed publications on pemetrexed's development and clinical application in NSCLC.
- Analysis of key Phase II and Phase III clinical trials.
Main Results:
- Pemetrexed, a multitargeted antifolate, demonstrates efficacy in first- and second-line advanced NSCLC treatment.
- Efficacy appears to differ between squamous and nonsquamous NSCLC histologies, with potential reasons explored.
- Pemetrexed's role in maintenance therapy for NSCLC is also discussed.
Conclusions:
- Pemetrexed is an effective treatment for advanced NSCLC with a favorable toxicity profile.
- Nonsquamous NSCLC tumors show improved outcomes with pemetrexed compared to squamous cell tumors.
- Pemetrexed may serve a role in NSCLC maintenance therapy.
More Related Videos
09:02Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017